

Barcelona, November 24 2014

## **SIGNIFICANT EVENT**

# **ACLIDINIUM + FORMOTEROL COMBINATION APPROVED IN EUROPE**

Almirall, S.A. (ALM.MC), as per section 82 of the Securities Market Act (Ley 24/1988 on 28 July, that regulates the Stock Market or *Mercado de Valores* in Spain) and other applicable provisions, hereby announces that:

The European Commission (EC) has authorised the marketing of the aclidinium + formoterol combination as a maintenance bronchodilator treatment to relieve symptoms in patients with Chronic Obstructive Pulmonary Disease (COPD) in all the Member States of the European Union.

Almirall has granted AstraZeneca the licensing rights in Europe of the aclidinium + formoterol combination in the agreement that was announced on November 3<sup>rd</sup>, 2014. Part of that agreement states that AstraZeneca will pay Almirall 150 million dollars when the first unit is sold in any country within the European Union.

The aclidinium + formoterol combination will be available in certain countries within the European Union during the first months of 2015.

Yours sincerely,

Pablo Divasson del Fraile

Investor Relations  
[inversores@almirall.com](mailto:inversores@almirall.com)

